RRC ID 45031
Author Yano A, Oda S, Fukami T, Nakajima M, Yokoi T.
Title Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury.
Journal Toxicol. Lett.
Abstract Drug-induced liver injury (DILI) is a major safety concern in drug development and clinical pharmacotherapy. However, prediction of DILI is difficult because the underlying mechanisms are not fully understood. To establish a novel cell-based screening system to suggest drugs with hepatotoxic potential in preclinical drug development, comprehensive gene expression analyses during in vivo DILI are necessary. Using in vivo mouse DILI models and 4 sets of hepatotoxic positive and non-hepatotoxic drugs, we found that the hepatic mRNA levels of S100A8; S100A9; "NATCH, LRR, and pyrin domain-containing protein 3" (NALP3); interleukin (IL)-1β; and the receptor for advanced glycation endproducts (RAGE) were commonly increased in hepatotoxic drug-administered mice compared to non-hepatotoxic drug-administered mice. To clarify whether these 5 in vivo biomarkers can be applied to a cell-based screening system, we adapted human liver microsomes (HLM) in the presence of NADPH to assess the metabolic activation reaction, and we also adapted human monocytic leukemia cells HL-60, K562, KG-1 and THP-1 to assess the effects on mRNA expression of immune- and inflammatory-related factors. We investigated 30 clinical drugs with different safety profiles with regard to DILI and found that the total sum score of gene expression levels of S100A8, S100A9, RAGE, NALP3 and IL-1β mRNA in HL-60 or K562 cells incubated with HLM, could identify drugs at high risk for hepatotoxicity. We proposed the use of the total sum score of gene expression level for assessing metabolic activation by drug-metabolizing enzymes and immune- and inflammatory-related factors for the risk assessment of DILI in preclinical drug development.
Volume 228(1)
Pages 13-24
Published 2014-7-3
DOI 10.1016/j.toxlet.2014.04.005
PII S0378-4274(14)00157-X
PMID 24747151
MeSH Adjuvants, Immunologic / pharmacology Alanine Transaminase / blood Animals Aspartate Aminotransferases / blood Biological Assay / methods* Biomarkers / metabolism Chemical and Drug Induced Liver Injury / metabolism Chemical and Drug Induced Liver Injury / pathology* Female Gene Expression / drug effects Humans Immunity, Cellular / drug effects* Inflammation / pathology* Mice Mice, Inbred BALB C Pharmaceutical Preparations / metabolism* RNA, Messenger / biosynthesis RNA, Messenger / genetics Real-Time Polymerase Chain Reaction Risk Assessment Toll-Like Receptor 4 / antagonists & inhibitors Tumor Cells, Cultured
IF 3.499
Times Cited 12
Human and Animal Cells